The Biological Half-life of Plasmin-treated Human Immunoglobulin in Blood

DOI Web Site PubMed
  • KANEKO Haruo
    The First Department of Internal Medicine, School of Medicine, Toho University
  • SHIRAI Tatsuo
    The First Department of Internal Medicine, School of Medicine, Toho University
  • YAMAUCHI Mikio
    The First Department of Internal Medicine, School of Medicine, Toho University
  • UMEDA Masanori
    The First Department of Internal Medicine, School of Medicine, Toho University
  • TSUKAHARA Toshihiro
    The First Department of Internal Medicine, School of Medicine, Toho University
  • MAKI Kazumasa
    The First Department of Internal Medicine, School of Medicine, Toho University
  • WATANABE Soichiro
    The First Department of Internal Medicine, School of Medicine, Toho University
  • HIRAHARA Tetsuyuki
    The First Department of Internal Medicine, School of Medicine, Toho University
  • ISHIKAWA Itaru
    The First Department of Internal Medicine, School of Medicine, Toho University
  • KIGA Yutaka
    The First Department of Internal Medicine, School of Medicine, Toho University
  • TAKATSUKI Yoshio
    The First Department of Internal Medicine, School of Medicine, Toho University
  • 間崎 民夫
    The First Department of Internal Medicine, School of Medicine, Toho University
  • KATO Masako
    The First Department of Internal Medicine, School of Medicine, Toho University

Bibliographic Information

Other Title
  • プラスミン処理ヒト免疫グロブリンの血中消失半減期について
  • プラスミン ショリ ヒト メンエキ グロブリン ノ ケッチュウ ショウシツ ハ

Search this article

Description

Few reports on the half-life of gammaglobulin in various diseases have been published. The authors measured its half-life by 131I-labelled plasmin-treated human immunoglobulin in various disorders, especially in blood and liver diseases.<br>The blood samples were drawn from a case or two cases of AML, AMoL, CML in blastic crisis, aplastic anemia, SLE, cancer of the lung and gall bladder and liver cirrhosis.<br>The half-life of immunoglobulin was 5.1, 6.9 and 5.8 days in the patients with AML, AMoL and CML in blastic crisis, respectively. The half-life tended to be shorter in cases of leukemia complicated by infections and/or with many leukemic cells. The half-life of immunoglobulin in two cases of aplastic anemia was 5.3 and 6.2 days. The half-life was shorter in the febrile cases. The half-life was 6.7 and 7.1 days in two patients suffering from cirrhosis of the liver, and 10.5 days in the case of severe liver impairment in association with cancer of the bile-duct.<br>These results suggested that the immunoglobulin half-life in blood depends on the disease and became shorter in patients under severe conditions with complicated serious infections. These changes seem to be influenced by the metabolism of the immunoglobulin.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 21 (11), 1637-1645, 1980

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top